Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q13698

UPID:
CAC1S_HUMAN

ALTERNATIVE NAMES:
Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1

ALTERNATIVE UPACC:
Q13698; A4IF51; B1ALM2; Q12896; Q13934

BACKGROUND:
Cav1.1, the alpha-1S subunit of the voltage-gated calcium channel, is essential for L-type calcium currents in skeletal muscle, facilitating excitation-contraction coupling. This protein's interaction with RYR1 is crucial for calcium release and muscle contraction, underscoring its importance in muscle physiology.

THERAPEUTIC SIGNIFICANCE:
Cav1.1 dysfunction is implicated in various muscular disorders, such as Hypokalemic Periodic Paralysis, Malignant Hyperthermia, Thyrotoxic Periodic Paralysis, and Congenital Myopathy. Targeting Cav1.1's pathway offers a promising avenue for developing novel treatments for these debilitating diseases, making its study a priority in therapeutic research.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.